Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse

Journal of Clinical Investigation

Volumn 123, Issue 10, 2013, Pages 4344-4358

  Cheng, Joseph C ^a   Bai, Aiping ^a   Beckham, Thomas H ^a   Tucker Marrison, S ^a   Yount, Caroline L ^a   Young, Katherine ^a   Lu, Ping ^a   Bartlett, Anne M ^a   Wu, Bill X ^a   Keane, Barry J ^a   Armeson, Kent E ^b   Marshall, David T ^a   Keane, Thomas E ^a   Smith, Michael T ^a   Ellen Jones, E ^a   Drake Jr , Richard R ^a   Bielawska, Alicja ^a   Norris, James S ^a   Liu, Xiang ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID CERAMIDASE; TRANSCRIPTION FACTOR AP 1; AMIDE; ASAH1 PROTEIN, HUMAN; N-(1-(4-NITROPHENYL)-1,3-DIHYDROXYPROP-2-YL)TETRADECANAMIDE; PROPANOLAMINE DERIVATIVE; PROTEIN BINDING; PROTEIN C JUN; RADIOSENSITIZING AGENT; SPHINGOLIPID;

ADAPTATION; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CATABOLISM; CONTROLLED STUDY; DISEASE COURSE; FEEDBACK SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID METABOLISM; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN PROCESSING; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; ENZYME INDUCTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MOUSE; NEOPLASM RECURRENCE, LOCAL; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE;

ACID CERAMIDASE; AMIDES; ANIMALS; CELL LINE, TUMOR; ENZYME INDUCTION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; PROPANOLAMINES; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SPHINGOLIPIDS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885049170     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64791     Document Type: Article

References (111)

1. Nguyen PL, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29(12):1517-1524.
2. Sheets NC, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307(15):1611-1620.
3. National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 1. 2013. NCCN Web site. http://www.nccn. org/professionals/physician-gls/f- guidelines. asp#prostate. Accessed July 31, 2013.
4. Vora SA, et al. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. J Urol. 2013;190(2):521-526.
5. Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. Int J Radiat Oncol Biol Phys. 2003;57(3):629-634.
6. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010;28(16):2653-2659.
7. Alicikus ZA, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011;117(7):1429-1437.
8. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):686-692.
9. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2. 5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68(5):1424-1430.
10. Bolla M, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103-106.
11. Kuban DA, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67-74.
12. Dearnaley DP, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475-487.
13. Zietman AL, et al. Comparison of conventionaldose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA. 2005;294(10):1233-1239.
14. Chism DB, Horwitz EM, Hanlon AL, Pinover WH, Mitra RK, Hanks GE. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys. 2003;55(1):71-77.
15. Smit WG, Helle PA, van Putten WL, Wijnmaalen AJ, Seldenrath JJ, van der Werf-Messing BH. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990;18(1):23-29.
16. Lawton CA, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991;21(4):935-939.
17. Cuvillier O, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381(6585):800-803.
18. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004;4(8):604-616.
19. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139-150.
20. Morad SA, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 2013;13(1):51-65.
21. Adan-Gokbulut A, Kartal-Yandim M, Iskender G, Baran Y. Novel agents targeting bioactive sphingolipids for the treatment of cancer. Curr Med Chem. 2013;20(1):108-122.
22. Beckham TH, Cheng JC, Marrison ST, Norris JS, Liu X. Interdiction of sphingolipid metabolism to improve standard cancer therapies. Adv Cancer Res. 2013;117:1-36.
23. Vit JP, Rosselli F. Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis. Oncogene. 2003;22(54):8645-8652.
24. Kimura K, Markowski M, Edsall LC, Spiegel S, Gelmann EP. Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells. Cell Death Differ. 2003;10(2):240-248.
25. Deng X, et al. Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of C. elegans. Science. 2008;322(5898):110-115.
26. Hara S, et al. p53-Independent ceramide formation in human glioma cells during [gamma]-radiation-induced apoptosis. Cell Death Differ. 2004;11(8):853-861.
27. Haimovitz-Friedman A, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med. 1994;180(2):525-535.
28. Verheij M, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 1996;380(6569):75-79.
29. Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J, Weichselbaum RR. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res. 1997;57(7):1270-1275.
30. Chmura SJ, et al. Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol Pharmacol. 2000;57(4):792-796.
31. Santana P, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 1996;86(2):189-199.
32. Bruno AP, et al. Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation. Cell Death Differ. 1998;5(2):172-182.
33. Bonnaud S, et al. Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. Cancer Res. 2010;70(23):9905-9915.
34. Otala M, et al. Protection from radiation-induced male germ cell loss by sphingosine-1-phosphate. Biol Reprod. 2004;70(3):759-767.
35. Morita Y, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med. 2000;6(10):1109-1114.
36. Samsel L, et al. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate. 2004;58(4):382-393.
37. Alphonse G, Bionda C, Aloy MT, Ardail D, Rousson R, Rodriguez-Lafrasse C. Overcoming resistance to gamma-rays in squamous carcinoma cells by polydrug elevation of ceramide levels. Oncogene. 2004;23(15):2703-2715.
38. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene. 2003;22(37):5897-5906.
39. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med. 2011;364(4):340-350.
40. Elojeimy S, et al. Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther. 2007;15(7):1259-1263.
41. Gouaze-Andersson V, et al. Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. Prostate. 2011;71(10):1064-1073.
42. Saad AF, et al. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007;6(9):1455-1460.
43. Szulc ZM, et al. Novel analogs of d-e-MAPP and B13. Part 1: Synthesis and evaluation as potential anticancer agents. Bioorg Med Chem. 2008;16(2):1015-1031.
44. Bielawska A, et al. Novel analogs of d-e-MAPP and B13. Part 2: Signature effects on bioactive sphingolipids. Bioorg Med Chem. 2008;16(2):1032-1045.
45. Liu X, et al. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006;14(5):637-646.
46. Eto M, Bennouna J, Hunter OC, Lotze MT, Amoscato AA. Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells. Int J Urol. 2006;13(2):148-156.
47. Noda S, et al. Role of ceramide during cisplatin-induced apoptosis in C6 glioma cells. J Neurooncol. 2001;52(1):11-21.
48. Hara S, et al. Ceramide triggers caspase activation during gamma-radiation-induced apoptosis of human glioma cells lacking functional p53. Oncol Rep. 2004;12(1):119-123.
49. Mahdy AE, et al. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009;17(3):430-438.
50. Thomas RL, Matsko CM, Lotze MT, Amoscato AA. Mass spectrometric identification of increased C16 ceramide levels during apoptosis. J Biol Chem. 1999;274(43):30580-30588.
51. Wang E, Norred WP, Bacon CW, Riley RT, Merrill AH. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. J Biol Chem. 1991;266(22):14486-14490.
52. Horvath A, Sutterlin C, Manning-Krieg U, Movva NR, Riezman H. Ceramide synthesis enhances transport of GPI-anchored proteins to the Golgi apparatus in yeast. EMBO J. 1994;13(16):3687-3695.
53. Hurwitz R, Ferlinz K, Sandhoff K. The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler. 1994;375(7):447-450.
54. Lucki N, Sewer MB. The cAMP responsive element binding protein (CREB) regulates the expression of acid ceramidase (ASAH1) in H295R human adrenocortical cells. Biochim Biophys Acta. 2009;1791(8):706-713.
55. Lucki NC, Bandyopadhyay S, Wang E, Merrill AH, Sewer MB. Acid ceramidase (ASAH1) is a global regulator of steroidogenic capacity and adrenocortical gene expression. Mol Endocrinol. 2012;26(2):228-243.
56. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene. 1993;8(4):877-886.
57. Domann FE, Levy JP, Birrer MJ, Bowden GT. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ. 1994;5(1):9-16.
58. Dong Z, et al. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol Carcinog. 1997;19(3):204-212.
59. Bedia C, Casas J, Andrieu-Abadie N, Fabrias G, Levade T. Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine. J Biol Chem. 2011;286(32):28200-28209.
60. Norris JS, et al. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006;13(12):1045-1051.
61. Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer. 2000;29(2):137-146.
62. Selzner M, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 2001;61(3):1233-1240.
63. Saddoughi SA, et al. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C (1) (8)-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011;17(18):6097-6105.
64. Koybasi S, et al. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem. 2004;279(43):44311-44319.
65. Siddique MM, et al. Ablation of dihydroceramide desaturase confers resistance to etoposide-induced apoptosis in vitro. PLoS One. 2012;7(9):e44042.
66. Liao WC, et al. Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase. J Biol Chem. 1999;274(25):17908-17917.
67. Cheng Y, et al. Identification of aberrant forms of alkaline sphingomyelinase (NPP7) associated with human liver tumorigenesis. Br J Cancer. 2007;97(10):1441-1448.
68. Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther. 2012;11(9):1841-1851.
69. White-Gilbertson S, et al. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene. 2009;28(8):1132-1141.
70. Mesicek J, et al. Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell Signal. 2010;22(9):1300-1307.
71. Ardail D, et al. Diversity and complexity of ceramide generation after exposure of jurkat leukemia cells to irradiation. Int J Radiat Oncol Biol Phys. 2009;73(4):1211-1218.
72. Merrill AH, van Echten G, Wang E, Sandhoff K. Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J Biol Chem. 1993;268(36):27299-27306.
73. Alphonse G, et al. p53-independent early and late apoptosis is mediated by ceramide after exposure of tumor cells to photon or carbon ion irradiation. BMC Cancer. 2013;13:151.
74. Wu WK, et al. The autophagic paradox in cancer therapy. Oncogene. 2012;31(8):939-953.
75. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res. 2008;68(5):1485-1494.
76. Ferrer I, Barron S, Rodriquez-Farre E, Planas AM. Ionizing radiation-induced apoptosis is associated with c-Jun. expression and c-Jun/AP-1 activation in the developing cerebellum of the rat. Neurosci Lett. 1995;202(1-2):105-108.
77. Lee YJ, et al. Effect of ionizing radiation on AP-1 binding activity and basic fibroblast growth factor gene expression in drug-sensitive human breast carcinoma MCF-7 and multidrug-resistant MCF-7/ADR cells. J Biol Chem. 1995;270(48):28790-28796.
78. Jegga AG, Schneider L, Ouyang X, Zhang J. Systems biology of the autophagy-lysosomal pathway. Autophagy. 2011;7(5):477-489.
79. Pchejetski D, et al. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010;70(21):8651-8661.
80. Hannun YA, Obeid LM. Many ceramides. J Biol Chem. 2011;286(32):27855- 27862.
81. Liu YY, et al. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J. 2008;22(7):2541-2551.
82. Kim WH, Kang KH, Kim MY, Choi KH. Induction of p53-independent p21 during ceramide-induced G1 arrest in human hepatocarcinoma cells. Biochem Cell Biol. 2000;78(2):127-135.
83. Alesse E, Zazzeroni F, Angelucci A, Giannini G, Di Marcotullio L, Gulino A. The growth arrest and downregulation of c-myc transcription induced by ceramide are related events dependent on p21 induction, Rb underphosphorylation and E2F sequestering. Cell Death Differ. 1998;5(5):381-389.
84. Komori H, Ichikawa S, Hirabayashi Y, Ito M. Regulation of UDP-glucose:ceramide glucosyltransferase-1 by ceramide. FEBS Lett. 2000;475(3):247-250.
85. Gamard CJ, Dbaibo GS, Liu B, Obeid LM, Hannun YA. Selective involvement of ceramide in cytokine-induced apoptosis. Ceramide inhibits phorbol ester activation of nuclear factor kappaB. J Biol Chem. 1997;272(26):16474-16481.
86. Ogretmen B, Kraveka JM, Schady D, Usta J, Hannun YA, Obeid LM. Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line. J Biol Chem. 2001;276(35):32506-32514.
87. Truman JP, et al. Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. J Biol Chem. 2005;280(24):23262-23272.
88. Ogretmen B, et al. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J Biol Chem. 2002;277(15):12960-12969.
89. Mechta F, Lallemand D, Pfarr CM, Yaniv M. Transformation by ras modifies AP1 composition and activity. Oncogene. 1997;14(7):837-847.
90. Alani R, et al. The transactivating domain of the c-Jun. proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol. 1991;11(12):6286-6295.
91. Johnson R, Spiegelman B, Hanahan D, Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol. 1996;16(8):4504-4511.
92. Schutte J, Minna JD, Birrer MJ. Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Haras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A. 1989;86(7):2257-2261.
93. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, Khachigian LM. Effect of deoxyribozymes targeting c-Jun. on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst. 2004;96(9):683-696.
94. Bohmann D, Bos TJ, Admon A, Nishimura T, Vogt PK, Tjian R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science. 1987;238(4832):1386-1392.
95. Ludes-Meyers JH, Liu Y, Munoz-Medellin D, Hilsenbeck SG, Brown PH. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001;20(22):2771-2780.
96. Smith LM, Birrer MJ, Stampfer MR, Brown PH. Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res. 1997;57(14):3046-3054.
97. O'Neill SM, Houck KL, Yun JK, Fox TE, Kester M. AP-1 binding transcriptionally regulates human neutral ceramidase. Arch Biochem Biophys. 2011;511(1-2):31-39.
98. Park JH, Eliyahu E, Narla G, DiFeo A, Martignetti JA, Schuchman EH. KLF6 is one transcription factor involved in regulating acid ceramidase gene expression. Biochim Biophys Acta. 2005;1732(1-3):82-87.
99. Halpern MT, Yabroff KR. Prevalence of outpatient cancer treatment in the United States: estimates from the Medical Panel Expenditures Survey (MEPS). Cancer Invest. 2008;26(6):647-651.
100. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104(6):1129-1137.
101. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5(7):516-525.
102. Beckham TH, et al. Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B. Int J Cancer. 2012;131(9):2034-2043.
103. Narita M, et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science. 2011;332(6032):966-970.
104. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006;6(10):764-775.
105. Bernardo K, et al. Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem. 1995;270(19):11098-11102.
106. Bai A, et al. Synthesis and bioevaluation of [omega]-N-amino analogs of B13. Bioorg Med Chem. 2009;17(5):1840-1848.
107. Thalmann GN, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54(10):2577-2581.
108. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994;57(3):406-412.
109. Zeidan YH, et al. Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-(alpha)-induced PGE2 production. J Biol Chem. 2006;281:24695-24703.
110. Xu R, Sun W, Jin J, Obeid LM, Mao C. Role of alkaline ceramidases in the generation of sphingosine and its phosphate in erythrocytes. FASEB J. 2010;24(7):2507-2515.
111. Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res. 1984;99(1):73-84.